Past two years Past Year Past 30 Days
Abstract Views 438 106 0
Full Text Views 7 1 0
PDF Downloads 5 2 0
 
 
 
 
 
 
 
 
 
 
 

Inactivated Western Equine Encephalomyelitis Vaccine Propagated in Chick Embryo Cell Culture

Clinical and Serological Evaluation in Man

Peter J. BartelloniU.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland 21701

Search for other papers by Peter J. Bartelloni in
Current site
Google Scholar
PubMed
Close
,
Robert W. McKinneyU.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland 21701

Search for other papers by Robert W. McKinney in
Current site
Google Scholar
PubMed
Close
,
Frank M. CaliaU.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland 21701

Search for other papers by Frank M. Calia in
Current site
Google Scholar
PubMed
Close
,
Helen H. RamsburgU.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland 21701

Search for other papers by Helen H. Ramsburg in
Current site
Google Scholar
PubMed
Close
, and
Francis E. Cole Jr.U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland 21701

Search for other papers by Francis E. Cole Jr. in
Current site
Google Scholar
PubMed
Close
View More View Less
Restricted access

A formalin-inactivated Western equine encephalomyelitis (WEE) vaccine prepared in chick embryo cell cultures was evaluated in man. Only occasional mild reactions were noted in 15 volunteers; no meaningful changes occurred in clinical laboratory values during the 12-day observation period. The mean log10 serum neutralizing indicies (LNI's) were comparable for volunteers given either two 0.5-ml doses of vaccine 28 days apart or a 0.5-ml dose followed by a 0.25-ml dose on day 28. Further evaluation in 21 “at-risk” laboratory workers, virgin to WEE virus, supported the data obtained in the volunteer studies; 92% of those given the 0.5-ml to 0.5-ml series achieved LNI's ≥1.7 by 28 days after the second dose, while 88% responded similarly in the 0.5-ml to 0.25-ml group. Vaccine used as a booster in 43 persons with prior WEE experience demonstrated high immunogenicity. At the time of the 0.1-ml intradermal booster dose, 88% of these persons had LNI's of <1.7, whereas by day 28 postvaccination 95% of these had achieved LNI's ≥1.7.

Author Notes

Present address: University of Maryland College of Medicine, Department of Medicine, Green Street, Baltimore, Maryland 21201.

Save